A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess safety and efficacy at months 3 and 6 in patients
with Langerhans Cell Histiocytosis given daily oral doses of GSK2110183.